Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib

A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Digoxin in
Healthy Subjects When Administered Alone and in Combination with a Single Dose of Vandetanib
(CAPRELSA) 300 mg

Inclusion Criteria:

- Provision of signed and dated, written informed consent prior to any study

- specific procedures Volunteers must be males or females aged 18 to 45 years and with
a weight of at least 50 kg and body mass index (BMI) between 18 and 30 kg/m2,

- inclusive Females must have a negative pregnancy test at screening and on admission
to the study center. Females must not be lactating and must be of non-childbearing
potential defined as postmenopausal or documentation of irreversible surgical
sterilization.

Exclusion Criteria:

- History of any clinically significant disease or disorder such as gastrointestinal,
hepatic, renal or skin disease.

- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity,

- Volunteers who are current smokers and have smoked or used nicotine products within
the previous 6 months

- Screening blood pressure of greater than 140/90 mmHg and/or a resting heart rate of
less than 45 beats per minute (repeat test allowed at the Investigator's discretion

- Clinically significant abnormal12-lead ECG as assessed by the Investigator, QTcF
interval greater than 450 ms

- Any positive result on screening for serum hepatitis B surface antigen, hepatitis C
antibody, and human immunodeficiency virus (HIV), or positive screen for drugs of
abuse.